Stella Pharma Corporation (4888.T)
- Previous Close
320.00 - Open
313.00 - Bid 314.00 x --
- Ask 316.00 x --
- Day's Range
313.00 - 323.00 - 52 Week Range
265.00 - 602.00 - Volume
49,100 - Avg. Volume
243,626 - Market Cap (intraday)
11.156B - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-22.91 - Earnings Date May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.
www.stella-pharma.co.jpRecent News: 4888.T
View MorePerformance Overview: 4888.T
Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4888.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4888.T
View MoreValuation Measures
Market Cap
10.89B
Enterprise Value
7.99B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
38.23
Price/Book (mrq)
3.54
Enterprise Value/Revenue
28.05
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-206.50%
Return on Assets (ttm)
-9.27%
Return on Equity (ttm)
-23.64%
Revenue (ttm)
323M
Net Income Avi to Common (ttm)
-667M
Diluted EPS (ttm)
-22.91
Balance Sheet and Cash Flow
Total Cash (mrq)
3.45B
Total Debt/Equity (mrq)
27.34%
Levered Free Cash Flow (ttm)
--